Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Test Developed to Predict Sepsis in Burns Patients

By LabMedica International staff writers
Posted on 13 Jul 2016
The diagnosis of sepsis represents a major clinical challenge as many classical diagnostic biomarkers are masked by the ongoing systemic inflammatory response syndrome following major burn injury.

A potentially life-saving new test has been developed that will allow clinicians to predict which burn victims will develop sepsis during their treatment. The test uses just three biomarkers of neutrophil function on the day of injury and can determine which patients with major burn injuries are likely to become septic.

Scientists at the University of Birmingham (UK) recruited 63 consecutive patients with burns into prospective cohort study within 24 hours of their injury. Blood samples were collected at fixed intervals following injury from day 1until 12 months. Those patients who died during the study and those patients who were lost to follow-up were included in the analysis. The source of sepsis for each episode was made through prospective recording of adverse events during the study. Pneumonia and ventilator-associated pneumonia (VAP), urinary tract infection (UTI), and central line associated blood stream infection (CLABSI) were diagnosed according to the US Centres for Disease Control (CDC, Atalnta, GA, USA) criteria.

Whole blood cell counts were performed on EDTA anticoagulated blood using the Sysmex XN-1000 hematology analyzer (Sysmex UK, Milton Keynes, UK). The measurement of neutrophil phagocytosis and oxidative burst was performed using the commercially available PhagoTEST and Phago- BURST kits (BD Biosciences, Oxford, UK). Both assays, using 10,000 neutrophils, were analyzed on the BD Bioscience Accuri C6 flow cytometer. The investigators also prepared platelet-free plasma, analyzed plasma and serum cell free DNA (cfDNA), performed reat time quantative polymerase chain rections, Western Blots and fluorescent micrsocpy.

The scientists found that neutrophil function was reduced for 28 days postburn injury and to a greater degree in patients who developed sepsis, which was also characterized by elevated immature granulocyte counts (IG) counts. The combination of neutrophil phagocytic capacity, plasma cfDNA levels, and IG count at day one postinjury gave good discriminatory power for the identification of septic patients.

Janet M. Lord, PhD, FmedSci, who jointly led the study said, “Our data showed that IG count could accurately discriminate between septic and non-septic patients, even with the complications that systemic inflammatory response syndrome has caused for other potential biomarkers. In addition to this, when we used a combination of two or more of our biomarkers, the discriminatory power was further enhanced.” The study was published online in June 2016 in the journal Annals of Surgery.

Related Links:
University of Birmingham
US Centres for Disease Control
Sysmex
BD Biosciences

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
HIV Test
Anti-HIV (1/2) Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.